FDA Clears Cercare Medical's Brain Tumor Segmentation AI

FDA clears Cercare Medical's AI tool for brain tumor segmentation, designed to automatically delineate tumor boundaries on MR imaging to assist radiologists.

• The clearance is a 510(k) for a software tool that automates brain tumor segmentation on MRI.
• The announcement is a vendor/press report; specific performance metrics (e.g., Dice score, sensitivity) were not detailed in the source snippet.
• As a device clearance, the tool demonstrates substantial equivalence to a predicate device, not necessarily a novel clinical-outcome improvement.

RadPigeon summaries are original and for information only. They are not clinical advice.